Company intelligence
Celtarys Research
Innovative Chemistry to Illuminate Biology
About Celtarys Research
Celtarys Research develops and commercializes new chemical tools to spread the use of fluorescence-based methods in drug discovery. Our chemical conjugation technology allows us to develop in a competitive manner and short time (<3 months) customized fluorescent ligands with optimal pharmacological and photophysical properties for any druggable target. We have initially applied our technology to develop versatile fluorescent GPCR ligands which we have externally validated in several HTS assays such as FRET, Fluorescence Polarization, High Content Screening or Flow Cytometry, avoiding the use of radioactivity. Products: We have a catalogue of 20 fluorescent ligands for different families of GPCRs, including adenosine, dopamine, serotonin, cannabinoid and muscarinic receptors. Compared to other available fluorescence-based technologies, our ligands are: -More flexible and efficient -With high affinity and selectivity for the target -With a wide variety of fluorochromes -Compatible with various assays: FRET, polarized fluorescence, High Content Screening, flow cytometry... -Rational design portfolio covering entire GPCR families - With low cost and scalable production Services: We also offer custom synthesis of specific fluorescent ligands for any target with therapeutic potential. Our technology allows us to develop in a competitive way and in a short time (<3 months) customized fluorescent ligands with optimal pharmacological and photophysical properties.
Verified activity
Signals from Celtarys Research
4 published signals
Research & Knowledge
Celtarys Research developed VHL and CRBN binding assay kits to test engagement in PROTAC and molecular glue projects.
Reported by Maria Majellaro
Partnerships
Celtarys Research partnered with Orionis Biosciences for a $40M upfront deal and up to $1.4B in milestones to design molecular glues for targets once considered undruggable.
Reported by Maria Majellaro
Products & Services
Celtarys Research is now doubling down on protein degraders, which saw its first FDA-approved drug this May.
Reported by Maria Majellaro
Presence & Recognition
Celtarys Research made headlines across Galician media.
Reported by Maria Majellaro